Previous Close | 5.21 |
Open | 5.03 |
Bid | 4.80 x 900 |
Ask | 5.21 x 100 |
Day's Range | 4.85 - 5.30 |
52 Week Range | 2.31 - 5.95 |
Volume | |
Avg. Volume | 29,662 |
Market Cap | 27.642M |
Beta (5Y Monthly) | 1.02 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.14 |
Earnings Date | May 09, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 33.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for LPCN
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company today announced positive topline results from a Phase 2 clinical study of LPCN 1148. LPCN 1148 is an oral candidate under development for the clinical management of cirrhosis, specifically prevention of OHE recurrence and treatment of sarcopenia. LPCN 1148 is targeted to be a "First in Class" product candidate with a novel mechanism of action (MOA). Lipocine plans to meet with the FDA to discuss a development path to NDA filing.
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform, today announced that study enrollment is complete and the first cohort of subjects has been dosed in pivotal pharmacokinetic (PK) study designed to support a New Drug Application (NDA) for LPCN 1154. LPCN 1154, oral brexanolone, is being developed by Lipocine for the treatment of postpartum depression (PPD).
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders, today announced financial results for the year ended December 31, 2023 and provided a corporate update.